New research from The University of Texas MD Anderson Cancer Center suggests psilocybin may protect sensory nerves from damage caused by chemotherapy, raising the possibility that compounds acting on psychedelic-related pathways could have applications beyond mental health.
The study, published in Science on 3 September 2026, found that psilocybin prevented chemotherapy-induced peripheral neuropathy (CIPN) in several preclinical models.
Peripheral neuropathy is a common side effect of some chemotherapy drugs and can cause burning, numbness, tingling and pain, particularly in the hands and feet. In some patients, symptoms can persist for months or years after chemotherapy has ended.
In the study, researchers gave mice two doses of psilocybin before exposing them to chemotherapy. The animals were then monitored through repeated chemotherapy cycles, with the researchers reporting that psilocybin prevented the development of neuropathy and that the protective effect remained during an eight-month observation period.
The researchers also found no evidence that psilocybin interfered with chemotherapy’s ability to target tumours.
The study investigated the biological mechanism behind the apparent neuroprotective effect, focusing on the serotonin 5-HT2A receptor and the movement of mitochondria within sensory neurons.
Mitochondria produce the energy cells need to function. In sensory neurons, which can extend considerable distances from the spinal cord to nerve endings in the hands and feet, mitochondria need to be transported along the length of the neuron to supply those distant areas with energy.
Chemotherapy can disrupt this mitochondrial transport and contribute to damage at sensory nerve endings. The researchers found that psilocybin helped preserve mitochondrial trafficking in these neurons, which they linked to protection against chemotherapy-related nerve damage.
The researchers then tested whether the effect depended on psilocybin’s psychedelic properties. They found that a non-hallucinogenic compound capable of activating the same 5-HT2A receptor pathway could also reproduce the neuroprotective effect.
This finding points towards the possibility of developing medicines that target some of the biological pathways associated with psychedelics without producing the subjective effects associated with psychedelic drugs.
For the psychedelic medicine field, the research adds to a growing body of work examining the effects of these compounds at the cellular and molecular level, rather than focusing solely on their psychological effects.
The potential implications extend into areas including pain and neurology, although the current findings remain a long way from demonstrating a new treatment for patients receiving chemotherapy.
The study was conducted using mice and laboratory models, meaning it does not establish whether psilocybin can prevent chemotherapy-induced neuropathy in humans. Clinical studies will be needed to determine whether the effect translates to people, as well as establish appropriate dosing and assess safety across different chemotherapy drugs and treatment regimens.
Psilocybin therefore cannot currently be considered a treatment for chemotherapy-induced peripheral neuropathy. The findings instead provide a basis for further research into whether activation of the 5-HT2A pathway can protect sensory neurons from chemotherapy-related damage.
If the mechanism can be replicated in human studies, it could provide a route towards psychedelic-derived medicines for conditions that have little connection to the traditional psychiatric applications of psychedelics.
Source: The University of Texas MD Anderson Cancer Center; Science, 3 September 2026.
